Berry Genomics Co

Berry Genomics Co Tax Expense

The Income Tax Expense of Berry Genomics Co (000710.SZ) as of Oct 22, 2026 is 6.74 M CNY. In the previous year, Income Tax Expense was 17.42 M CNY — a change of -61.32% (lower).

Tax Expense

6.74 MCNY

YoY

-61.32%

Last updated:

Income Tax Expense of Berry Genomics Co is 2025 6.74 M CNY. Income Tax Expense of Berry Genomics Co was 2024 17.42 M CNY. It decreases by -61.32% lower compared to the previous year.

The Berry Genomics Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
51.17 M CNY
Jan 1, 2019
58.54 M CNY
Jan 1, 2020
39.65 M CNY
Jan 1, 2021
-10.52 M CNY
Jan 1, 2022
-29.98 M CNY
Jan 1, 2023
-28.16 M CNY
Jan 1, 2024
17.42 M CNY
Jan 1, 2025
6.74 M CNY
The Berry Genomics Co Tax Expense history
YEARTax ExpenseYoY
6.74 MCNY-61.32%
17.42 MCNY-161.85%
-28.16 MCNY-6.06%
-29.98 MCNY+184.98%
-10.52 MCNY-126.53%
39.65 MCNY-32.26%
58.54 MCNY+14.40%
51.17 MCNY+28.63%
39.78 MCNY+58.92%
25.03 MCNY+205.31%
8.20 MCNY-16.79%
9.85 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Berry Genomics Co Stock analysis

What does Berry Genomics Co do? Berry Genomics Co., Ltd. generates revenue through basic scientific research services, medical testing services, and the sale of reagents and equipment. The company provides transcriptome sequencing, human whole exome sequencing, and whole genome sequencing for scientific research clients. Medical testing services include tumor genetic testing, genetic disease testing, and reproductive health testing for healthcare providers. Reagent and equipment sales feature the NextSeq CN500 gene sequencer and general reagents for sequencing reactions, targeting research institutions and medical facilities. The primary buyers of basic scientific research services are research institutions requiring advanced sequencing platforms. Medical testing services are purchased by healthcare providers offering diagnostic solutions. Reagent and equipment sales target both research and medical sectors, with the NextSeq CN500 gene sequencer being a key product for high-throughput sequencing needs. The company's revenue streams are segmented by service type, with research services and medical testing forming the core business segments. Berry Genomics' product portfolio includes sequencing platforms, testing reagents, and equipment like the NextSeq CN500 gene sequencer. These products serve research institutions and medical facilities, with medical testing services focusing on tumor, genetic disease, and reproductive health applications. The company's sales strategy emphasizes high-throughput sequencing technology solutions for both scientific and medical markets. Berry Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Berry Genomics Co stock

Income Tax Expense of Berry Genomics Co is 6.74 M CNY in 2025.

Income Tax Expense of Berry Genomics Co changed from 17.42 M CNY to 6.74 M CNY, representing a -61.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Berry Genomics Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Berry Genomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Berry Genomics Co

All Key Metrics — Berry Genomics Co